# US 2024/0197931 A1 · Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197931 A1
- Document ID: US20240197931A1
- Status: Published application
- Kind: A1
- Application number: 18/553,757
- Filed: 2022-04-07
- Published: 2024-06-20
- Earliest claimed: 2021-04-07
- Assignees: Actinium Pharmaceuticals, Inc.
- Applicants: Actinium Pharmaceuticals, Inc.
- Inventors: Dale L LUDWIG; Eileen GEOGHEGAN; Sandesh SETH; Jesse HWANG
- Web page: https://patentgrep.com/patent/US20240197931A1

## CPC

- A61K 51/1033: {against receptors for cytokines, lymphokines or interferons}
- A61P 35/00: Antineoplastic agents
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4244: {Enzymes}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2121/00: Preparations for use in therapy
- A61K 2239/50: Colon
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are methods for treating a solid cancer in a subject by administering an effective amount of a radioconjugated CCR8-targeting agent to deplete tumor-associated CCR8-positive Treg cells, alone or in combination with one or more additional therapeutic agents or modalities, such as a radioconjugated CD33-targeting agent.

## Claims

### Claim 1

A method for treating a solid cancer in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a radiolabeled CCR8 targeting agent, wherein the radiolabeled CCR8 targeting agent comprises a radiolabel selected from 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, 212Pb, or any combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the solid cancer is a breast cancer, gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancer, stomach cancer, testicular cancer, esophageal cancer, bronchioloalveolar cancer, prostate cancer, colorectal cancer, ovarian cancer, cervical epidermoid cancer, pancreatic cancer, lung cancer, renal cancer, head and neck cancer, or any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the radiolabeled CCR8 targeting agent is an amount effective to deplete or ablate CCR8-positive Treg cells in the solid cancer, wherein the depletion or ablation is not mediated by ADCC.

### Claim 4 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount of the radiolabeled CCR8 targeting agent is an amount at least 10-fold lower than an unconjugated CCR8 targeting agent, or an amount at least 20-fold lower than the unconjugated CCR8 targeting agent, or an amount at least 30-fold lower than the unconjugated CCR8 targeting agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the radiolabeled CCR8 targeting agent is an amount effective to increase the amount and/or activity of immune cells that produce antitumor immunity.

### Claim 6 (depends on 1)

The method of claim 1, wherein the radioisotope radiolabeled CCR8 targeting agent is 225Ac-labeled, and the therapeutically effective amount of the 225Ac-labeled CCR8 targeting agent comprises:
a protein dose of less than 3 mg/kg body weight of the subject, such as from 0.001 mg/kg patient weight to 3.0 mg/kg patient weight, or from 0.005 mg/kg patient weight to 2.0 mg/kg patient weight, or from 0.01 mg/kg patient weight to 1 mg/kg patient weight, or from 0.1 mg/kg patient weight to 0.6 mg/kg patient weight, or 0.3 mg/kg patient weight, or 0.4 mg/kg patient weight, or 0.5 mg/kg patient weight, or 0.6 mg/kg patient weight; and
a radiation dose of 0.1 to 50 μCi/kg body weight of the subject, or 0.1 to 5 μCi/kg body weight of the subject, or 5 to 20 μCi/kg subject body weight.

### Claim 7 (depends on 1)

The method of claim 1, wherein the radioisotope radiolabeled CCR8 targeting agent is 225Ac-labeled, and the therapeutically effective amount of the 22′Ac-labeled CCR8 targeting agent comprises:
a protein dose of less than 3 mg/kg body weight of the subject, such as from 0.001 mg/kg patient weight to 3.0 mg/kg patient weight, or from 0.005 mg/kg patient weight to 2.0 mg/kg patient weight, or from 0.01 mg/kg patient weight to 1 mg/kg patient weight, or from 0.1 mg/kg patient weight to 0.6 mg/kg patient weight, or 0.3 mg/kg patient weight, or 0.4 mg/kg patient weight, or 0.5 mg/kg patient weight, or 0.6 mg/kg patient weight; and
a radiation dose of 2 μCi to 2mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the radiolabeled CCR8 targeting agent is administered as a single dose.

### Claim 9 (depends on 1)

The method of claim 1, wherein the radiolabeled CCR8 targeting agent is administered according to a dosing schedule selected from the group consisting of once every 7, 10, 12, 14, 20, 24, 28, 36, and 42 days throughout a treatment period, wherein the treatment period includes at least two doses.

### Claim 10 (depends on 1)

The method of claim 1, further comprising:
administering to the subject a therapeutically effective amount of an immune checkpoint therapy, a MICA blockade, a CD47 blockade, or any combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the immune checkpoint therapy comprises an antibody against PD-1, PD-L1, PD-L2, CTLA-4, TIM3, LAG3, VISTA, or any combination thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the CD47 blockade comprises magrolimab, lemzoparlimab, AO-176, TTI-621, TTI-622, ALX148, RRx-001, an agent that modulates CD47 expression, MBT-001, or any combination thereof.

### Claim 13 (depends on 10)

The method of claim 10, wherein the MICA blockade comprises a monoclonal antibody against MICA that stabilizes surface expression of MICA on tumor cells in the subject.

### Claim 14 (depends on 1)

The method of claim 1, further comprising:
administering to the subject a therapeutically effective amount of a DNA damage response inhibitor (DDRi), a chemotherapeutic agent, or any combination thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the DDRi comprises a poly(ADP-ribose) polymerase inhibitor (PARPi), an ataxia telangiectasia mutated inhibitor (ATMi), an ataxia talangiectasia mutated and Rad-3 related inhibitor (ATRi), or a Wee1 inhibitor.

### Claim 16 (depends on 14)

The method of claim 14, wherein the chemotherapeutic agent is a radiosensitizer.

### Claim 17 (depends on 1)

The method of claim 1, further comprising:
performing adoptive cell therapy on the subject to treat the solid cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the adoptive cell therapy comprises administering gene-edited CAR-T cells to the subject, wherein the gene-edited CAR-T cells fail to properly express at least one checkpoint receptor and/or at least one T cell receptor.

### Claim 19 (depends on 17)

The method of claim 17, wherein the adoptive cell therapy comprises administering to the subject an effective amount of a population of cells expressing a chimeric antigen receptor or an engineered T-cell receptor (CAR/TCR).

### Claim 20 (depends on 19)

The method of claim 19, wherein the population of cells expressing the CAR/TCR target CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CS-1, B-cell maturation antigen (BCMA), MAGEA3, MAGEA3/A6, KRAS, CLL1, MUC-1, HER2, EpCam, GD2, GPA7, PSCA, EGFR, EGFRvIII, ROR1, mesothelin, CD33/IL3Ra, c-Met, CD37, PSMA, Glycolipid F77, GD-2, gp100, NY-ESO-1 TCR, FRalpha, CD24, CD44, CD133, CD166, CA-125, HE4, Oval, estrogen receptor, progesterone receptor, uPA, PAI-1, MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 or ULBP6, or any combination thereof.

### Claim 21 (depends on 17)

The method of claim 17, wherein the adoptive cell therapy is performed simultaneous to administration of the radiolabeled CCR8 targeting agent, or is performed 4, 5, 6, 7, or 8 days after administration of the radiolabeled CCR8 targeting agent.

### Claim 22 (depends on 1)

The method of claim 1, further comprising:
administering a radiolabeled CD33 targeting agent to the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the radiolabeled CD33 targeting agent is a radiolabeled anti-CD33 antibody or a radiolabeled CD33-binding antibody fragment.

### Claim at position 24

24-39. (canceled)
